Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine kinase inhibitors (EGFR–TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchibori, Ken, Inase, Naohiko, Araki, Mitsugu, Kamada, Mayumi, Sato, Shigeo, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355811/
https://www.ncbi.nlm.nih.gov/pubmed/28287083
http://dx.doi.org/10.1038/ncomms14768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355811/
https://www.ncbi.nlm.nih.gov/pubmed/28287083
http://dx.doi.org/10.1038/ncomms14768

Ejemplares similares